Somerset, NJ, April 1, 2020 – Legend Biotech Corporation (Legend), a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that it has raised $150.5 million in Series A financing. Proceeds from the financing will be used to advance the research and development […]

Piscataway, NJ, January 28, 2020 – Legend Biotech announced that, according to the terms and conditions of an agreement with Janssen Biotech, Inc. (Janssen), the fourth milestone payment has been achieved relating to the U.S. clinical development of the B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, LCAR-B38M (JNJ-68284528 (JNJ-4528)). “We are pleased […]

Orlando, FL, December 9, 2019 – Legend Biotech reported updated data on the LEGEND-2 (NCT03090659) Phase1/2 open-label, first-in-human study, which evaluated the investigational chimeric antigen receptor T-cell (CAR-T) therapy, LCAR-B38M, in the treatment of patients with advanced relapsed and/or refractory multiple myeloma (RRMM) in China. LCAR-B38M is a structurally differentiated CAR-T cell therapy containing a […]

Orlando, FL, December 7, 2019 – Legend Biotech announced today initial results from the Janssen Research &Development, LLC (Janssen)-sponsored Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed and/or […]

Designation based on the ongoing U.S. Phase 1b/2 CARTITIUDE-1 (MMY2001, NCT03548207) study in advanced relapsed or refractory multiple myeloma PISCATAWAY, NJ, DECEMBER 6, 2019 – Legend Biotech USA Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to Janssen Research & Development, LLC (Janssen) for JNJ-68284528 (JNJ-4528), […]